I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter @theroberthart or email me at rhart@forbes.com
A Covid-19 antibody treatment developed by Vir Biotechnology and GlaxoSmithKline is still capable of neutralizing the infectious omicron subvariant, BA.2, Vir
Thursday, offering early hope that one of the only treatments shown to be effective against omicron will still be useful against the variant’s fast-spreading relative. Vir said the antibody treatment, sotrovimab, “retains neutralizing activity against the BA.2 subvariant of omicron,” according to laboratory studies on a modified virus designed to have the variant’s mutations.
The company said it is sharing the results with regulators around the world and plans to publish the data “in the coming week.”Vir chief executive George Scangos said the data supports the continued use of sotrovimab against Covid and suggests a standard dose of the therapy is “sufficient to retain activity against the BA.2 variant.” Sotrovimab, which is authorized for emergency use against Covid in the U.S., is one of the few treatments shown to be effective against the omicron variant.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Opinion | Covid Patients Suffer as the Biden Administration Tries to Practice MedicineFrom WSJopinion: Washington bureaucrats’ micromanagement of Covid-19 treatments that are safe and effective in varying circumstances has to stop, writes Joel Zinberg
Baca lebih lajut »
Travel nurses fear wage caps after bipartisan group of lawmakers ask White House to investigateWith COVID-19 hospitalizations still extremely elevated due to the spread of the highly contagious omicron variant, the need for nurses has never been higher.
Baca lebih lajut »
South Korea to roll out Novavax COVID-19 vaccine next weekSouth Korea will begin offering Novavax Inc.’s COVID-19 vaccine at hospitals, nursing homes and public health centers next week, adding another tool to fight a fast-developing omicron surge
Baca lebih lajut »
S.Korea turns to self-treatment as Omicron fuels COVID surgeSouth Korea said on Thursday patients with mild coronavirus symptoms will have to treat themselves, aiming to free up medical resources for more serious cases, as new infections hit a fresh high because of the fast spreading Omicron variant.
Baca lebih lajut »
Can Omicron Cause Long COVID?Many doctors think it is possible to have long-term effects from the omicron variant of the coronavirus though it is too soon to know for sure.
Baca lebih lajut »